New drug LAD603 put to the test in healthy volunteers
NCT ID NCT06200597
First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 21 times
Summary
This early-stage study tested the safety and tolerability of a new drug called LAD603 in 92 healthy adults aged 18 to 65. Participants received either the drug or a placebo to see how the body processes it and whether it causes side effects. The goal was not to treat any disease, but to gather important safety information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON Phase 1 unit Lenexa
Lenexa, Kansas, 66219, United States
Conditions
Explore the condition pages connected to this study.